

Supplementary Data

Supplementary Table 1: Enrollment of the study cohort	2
Supplementary Table 2: Distribution of baseline characteristics	3
Supplementary Table 3: Number of days until first dose	4
Supplementary Table 4: Number of Covid-19-related hospital admissions	5
Supplementary Table 5: Number of Covid-19-related ICU admissions	6
Supplementary Table 6: VE against Covid-19-related hospital admission	7
Supplementary Table 7: VE against Covid-19-related ICU admission	8
Supplementary Table 8: VE against Covid-19-related hospital admission by age group	9
Supplementary Table 9: VE against Covid-19-related hospital admission by presence of comorbidities	10
Supplementary Table 10: VE against Covid-19-related hospital admission in 2021 Q4	11
Supplementary Table 11: VE against Covid-19-related hospital admission in 2022 Q1	12
Supplementary Table 12: Negative control outcome analysis	13
Supplementary Figure 1: Distribution of SARS-CoV-2 variants by calendar month	14
Supplementary Figure 2: Distribution of exposure states by calendar month	15
Supplementary Figure 3: Number of cases by calendar month	16

Supplementary Table 1: Enrollment of the study cohort Individuals were excluded if they had experienced any of the listed events prior to the start of the study.

	Number of individuals
Target population	899796
Excluded due to prior laboratory-confirmed SARS-CoV-2 infection	1861
Excluded due to prior Covid-19-related hospital admission	<5
Excluded due to prior Covid-19-related ICU admission	<5
Excluded due to prior Covid-19 vaccination	<5
Study cohort	897932

Supplementary Table 2: Distribution of baseline characteristics

	n	%
Age in years		
70-79	583684	65
80-89	257634	29
90-115	56614	6
Sex		
Male	382545	43
Female	515387	57
Region of residence		
Helsinki-Uusimaa	216074	24
Åland	4902	1
Northern and Eastern Finland	223210	25
Southern Finland	214453	24
Western Finland	239293	27
In long-term care		
No	846793	94
Yes	51139	6
Influenza vaccination in 2019–2020		
No	395797	44
Yes	502135	56
Nights hospitalized between 2015 and 2019		
0	461810	51
1-5	191654	21
6-20	137738	15
21+	106730	12
Presence of comorbidities		
No predisposing comorbidities	375661	42
Moderately predisposing comorbidities only	203598	23
At least 1 highly predisposing comorbidity	318673	35
Presence of particular comorbidities		
Diabetes mellitus type 2	198173	22
Heart failure or ischemic heart disease	170420	19
Malignant neoplasms	112630	13
Asthma	75791	8
Chronic pulmonary disease	27474	3
Chronic renal disease	22174	2
Hematologic malignancy	15317	2
Diseases of myoneural junction and muscle	5837	1
Organ or stem cell transplant	2189	0
Cerebral palsy or other paralytic syndromes	1993	0
Severe disorders of the immune system	1462	0

Supplementary Table 3: Number of days until first dose Distribution of the number of days until the receipt of the first dose in the study of vaccine effectiveness against Covid-19-related hospital admission.

	Percentile		
	25th	50th	75th
Age in years			
70-79	80	92	102
80-89	50	60	73
90-115	32	52	66
Sex			
Male	66	86	100
Female	60	80	94
Region of residence			
Helsinki-Uusimaa	59	80	93
Åland	48	69	84
Northern and Eastern Finland	62	82	101
Southern Finland	65	85	100
Western Finland	64	81	95
In long-term care			
No	66	83	96
Yes	23	26	43
Influenza vaccination in 2019–2020			
No	64	86	102
Yes	61	80	94
Nights hospitalized between 2015 and 2019			
0	68	87	101
1-5	65	81	95
6-20	58	74	93
21+	38	61	87
Presence of comorbidities			
No predisposing comorbidities	66	86	100
Moderately predisposing comorbidities only	59	79	94
At least 1 highly predisposing comorbidity	60	80	95

Supplementary Table 4: Number of Covid-19-related hospital admissions by vaccine, dose and days since last vaccination. The table shows the number of cases and person-years, the cumulative risk (per 100000) at the end of the study estimated based on the Kaplan-Meier estimator, the number of study subjects who contributed person-time, the number of study subjects who were censored before the end of the study and the number of study subjects who were still considered at risk at the end of the study. Study subjects may have passed through multiple exposure states before becoming cases or being censored.

	Cases	P-years	Risk	Subjects	Censored	At risk
Not vaccinated	637	241629	888	897931	18190	35987
Comirnaty 0-20	47	40813	448	710603	1269	381
Comirnaty 21-83	77	114794	477	694803	6367	1863
Comirnaty 84+	24	9752	316	82420	4880	4177
Comirnaty + Comirnaty 0-13	7	26498	149	691666	628	364
Comirnaty + Comirnaty 14-90	30	143799	80	690669	7978	12847
Comirnaty + Comirnaty 91-180	193	156943	148	669079	9321	10327
Comirnaty + Comirnaty 181+	148	28696	265	501828	6729	26424
Comirnaty + Comirnaty + Comirnaty 0-13	38	20826	75	544671	585	2924
Comirnaty + Comirnaty + Comirnaty 14-60	79	64209	28	541162	6448	142486
Comirnaty + Comirnaty + Comirnaty 61+	66	22182	60	392228	5959	386269
Comirnaty + Comirnaty + Spikevax 0-13	9	2760	54	72377	69	934
Comirnaty + Comirnaty + Spikevax 14-60	13	6544	73	71374	482	57762
Comirnaty + Comirnaty + Spikevax 61+	7	516	259	13130	320	12810
Spikevax 0-20	<5	4905	381	85402	169	77
Spikevax 21-83	10	13876	465	85127	2338	638
Spikevax 84+	5	1604	452	13729	1829	790
Spikevax + Spikevax 0-13	<5	3047	9	79561	76	72
Spikevax + Spikevax 14-90	<5	16454	56	79412	1084	1944
Spikevax + Spikevax 91-180	30	17576	84	76213	1274	1973
Spikevax + Spikevax 181+	14	2962	151	52841	625	3459
Spikevax + Spikevax + Comirnaty 0-13	<5	649	108	17072	31	247
Spikevax + Spikevax + Comirnaty 14-60	<5	1924	90	16794	315	5313
Spikevax + Spikevax + Comirnaty 61+	0	544	0	11166	179	10987
Spikevax + Spikevax + Spikevax 0-13	5	1986	70	51982	68	363
Spikevax + Spikevax + Spikevax 14-60	5	5677	14	51551	634	21344
Spikevax + Spikevax + Spikevax 61+	<5	1379	21	29573	374	29199
Vaxzevria 0-20	<5	2744	14	47750	45	0
Vaxzevria 21-83	<5	7978	7	47693	5405	0
Vaxzevria 84+	<5	458	675	5114	2788	207
Vaxzevria + Vaxzevria 0-13	0	1506	0	39305	16	0
Vaxzevria + Vaxzevria 14-90	<5	8263	16	39289	208	0
Vaxzevria + Vaxzevria 91-180	23	9082	205	39032	400	23
Vaxzevria + Vaxzevria 181+	16	1064	280	24688	273	2191
Vaxzevria + Vaxzevria + Comirnaty 0-13	<5	911	49	23864	19	251
Vaxzevria + Vaxzevria + Comirnaty 14-60	<5	2535	24	23594	192	11827
Vaxzevria + Vaxzevria + Comirnaty 61+	<5	379	308	11575	75	11500
Vaxzevria + Vaxzevria + Spikevax 0-13	<5	470	30	12330	6	156
Vaxzevria + Vaxzevria + Spikevax 14-60	0	1117	0	12168	50	9517
Vaxzevria + Vaxzevria + Spikevax 61+	<5	63	55	2601	13	2588

Supplementary Table 5: Number of Covid-19-related ICU admissions by vaccine, dose and days since last vaccination. The table shows the number of cases and person-years, the cumulative risk (per 100000) at the end of the study estimated based on the Kaplan-Meier estimator, the number of study subjects who contributed person-time, the number of study subjects who were censored before the end of the study and the number of study subjects who were still considered at risk at the end of the study. Study subjects may have passed through multiple exposure states before becoming cases or being censored.

	Cases	P-years	Risk	Subjects	Censored	At risk
Not vaccinated	131	241644	157	897931	18148	36028
Comirnaty 0-20	10	40814	75	710604	1242	381
Comirnaty 21-83	8	114796	14	694831	6378	1867
Comirnaty 84+	<5	9753	67	82431	4890	4178
Comirnaty + Comirnaty 0-13	<5	26498	2	691668	624	364
Comirnaty + Comirnaty 14-90	<5	143800	8	690675	7974	12848
Comirnaty + Comirnaty 91-180	24	156948	13	669088	9282	10329
Comirnaty + Comirnaty 181+	14	28701	23	501874	6762	26436
Comirnaty + Comirnaty + Comirnaty 0-13	<5	20826	2	544672	549	2924
Comirnaty + Comirnaty + Comirnaty 14-60	9	64212	2	541199	6459	142491
Comirnaty + Comirnaty + Comirnaty 61+	8	22183	52	392249	5952	386297
Comirnaty + Comirnaty + Spikevax 0-13	<5	2760	15	72377	61	934
Comirnaty + Comirnaty + Spikevax 14-60	<5	6544	9	71382	488	57763
Comirnaty + Comirnaty + Spikevax 61+	0	516	0	13131	319	12812
Spikevax 0-20	0	4905	0	85402	166	77
Spikevax 21-83	<5	13876	4	85130	2341	638
Spikevax 84+	0	1604	0	13729	1829	790
Spikevax + Spikevax 0-13	0	3047	0	79561	75	72
Spikevax + Spikevax 14-90	0	16455	0	79413	1084	1944
Spikevax + Spikevax 91-180	<5	17577	2	76214	1271	1973
Spikevax + Spikevax 181+	0	2963	0	52845	629	3459
Spikevax + Spikevax + Comirnaty 0-13	0	650	0	17072	29	247
Spikevax + Spikevax + Comirnaty 14-60	0	1924	0	16796	317	5313
Spikevax + Spikevax + Comirnaty 61+	0	544	0	11166	179	10987
Spikevax + Spikevax + Spikevax 0-13	0	1986	0	51982	63	363
Spikevax + Spikevax + Spikevax 14-60	0	5677	0	51556	638	21344
Spikevax + Spikevax + Spikevax 61+	0	1379	0	29574	371	29203
Vaxzevria 0-20	0	2744	0	47750	42	0
Vaxzevria 21-83	<5	7979	4348	47696	5409	0
Vaxzevria 84+	0	458	0	5113	2787	207
Vaxzevria + Vaxzevria 0-13	0	1506	0	39305	16	0
Vaxzevria + Vaxzevria 14-90	<5	8263	10	39289	208	0
Vaxzevria + Vaxzevria 91-180	5	9083	13	39032	397	23
Vaxzevria + Vaxzevria 181+	<5	1065	71	24691	276	2191
Vaxzevria + Vaxzevria + Comirnaty 0-13	0	912	0	23864	17	251
Vaxzevria + Vaxzevria + Comirnaty 14-60	0	2536	0	23596	194	11827
Vaxzevria + Vaxzevria + Comirnaty 61+	<5	379	308	11575	75	11500
Vaxzevria + Vaxzevria + Spikevax 0-13	0	470	0	12330	5	156
Vaxzevria + Vaxzevria + Spikevax 14-60	0	1117	0	12169	51	9517
Vaxzevria + Vaxzevria + Spikevax 61+	0	63	0	2601	13	2588

Supplementary Table 6: VE against Covid-19-related hospital admission Vaccine effectiveness (in %) quantified as 1 minus the hazard ratio adjusted for age, sex, region of residence, residence in a long-term care facility, influenza vaccination in 2019–2020, number of nights hospitalized between 2015 and 2019 and presence of predisposing comorbidities.

	MLE	LCI	UCI	p-value ¹
Comirnaty 0-20	49	29	63	.
Comirnaty 21-83	64	52	73	.
Comirnaty 84+	66	49	78	.
Comirnaty + Comirnaty 0-13	84	67	93	.
Comirnaty + Comirnaty 14-90	93	90	95	.
Comirnaty + Comirnaty 91-180	87	84	89	.
Comirnaty + Comirnaty 181+	72	66	77	.
Comirnaty + Comirnaty + Comirnaty 0-13	91	87	93	.
Comirnaty + Comirnaty + Comirnaty 14-60	96	95	97	.
Comirnaty + Comirnaty + Comirnaty 61+	92	89	94	.
Comirnaty + Comirnaty + Spikevax 0-13	88	77	94	.
Comirnaty + Comirnaty + Spikevax 14-60	94	89	96	.
Comirnaty + Comirnaty + Spikevax 61+	59	13	81	.
Spikevax 0-20	72	26	90	.
Spikevax 21-83	69	41	84	.
Spikevax 84+	72	33	89	.
Spikevax + Spikevax 0-13	86	2	98	.
Spikevax + Spikevax 14-90	97	88	99	.
Spikevax + Spikevax 91-180	85	78	90	.
Spikevax + Spikevax 181+	81	67	89	.
Spikevax + Spikevax + Comirnaty 0-13	86	42	96	.
Spikevax + Spikevax + Comirnaty 14-60	94	83	98	.
Spikevax + Spikevax + Comirnaty 61+	100	.	.	<0.001
Spikevax + Spikevax + Spikevax 0-13	91	77	96	.
Spikevax + Spikevax + Spikevax 14-60	98	95	99	.
Spikevax + Spikevax + Spikevax 61+	93	82	98	.
Vaxzevria 0-20	31	-120	78	.
Vaxzevria 21-83	68	-2	90	.
Vaxzevria 84+	3	-161	64	.
Vaxzevria + Vaxzevria 0-13	100	.	.	0.122
Vaxzevria + Vaxzevria 14-90	83	53	94	.
Vaxzevria + Vaxzevria 91-180	76	62	84	.
Vaxzevria + Vaxzevria 181+	39	-1	63	.
Vaxzevria + Vaxzevria + Comirnaty 0-13	85	53	95	.
Vaxzevria + Vaxzevria + Comirnaty 14-60	97	89	99	.
Vaxzevria + Vaxzevria + Comirnaty 61+	91	33	99	.
Vaxzevria + Vaxzevria + Spikevax 0-13	92	40	99	.
Vaxzevria + Vaxzevria + Spikevax 14-60	100	.	.	<0.001
Vaxzevria + Vaxzevria + Spikevax 61+	42	-319	92	.

MLE, maximum likelihood estimate;

LCI/UCI, lower/upper limit of the 95% Wald confidence interval

¹ Likelihood-ratio test

Supplementary Table 7: VE against Covid-19-related ICU admission Vaccine effectiveness (in %) quantified as 1 minus the hazard ratio adjusted for age, sex, region of residence, residence in a long-term care facility, influenza vaccination in 2019–2020, number of nights hospitalized between 2015 and 2019 and presence of predisposing comorbidities.

	MLE	LCI	UCI	p-value ¹
Comirnaty 0-20	57	12	79	.
Comirnaty 21-83	84	62	93	.
Comirnaty 84+	64	-2	87	.
Comirnaty + Comirnaty 0-13	74	-15	94	.
Comirnaty + Comirnaty 14-90	97	91	99	.
Comirnaty + Comirnaty 91-180	93	88	96	.
Comirnaty + Comirnaty 181+	84	70	91	.
Comirnaty + Comirnaty + Comirnaty 0-13	99	91	100	.
Comirnaty + Comirnaty + Comirnaty 14-60	97	94	99	.
Comirnaty + Comirnaty + Comirnaty 61+	90	76	96	.
Comirnaty + Comirnaty + Spikevax 0-13	93	50	99	.
Comirnaty + Comirnaty + Spikevax 14-60	89	68	96	.
Comirnaty + Comirnaty + Spikevax 61+	100	.	.	0.061
Spikevax 0-20	100	.	.	0.017
Spikevax 21-83	67	-40	92	.
Spikevax 84+	100	.	.	0.034
Spikevax + Spikevax 0-13	100	.	.	0.135
Spikevax + Spikevax 14-90	100	.	.	<0.001
Spikevax + Spikevax 91-180	98	83	100	.
Spikevax + Spikevax 181+	100	.	.	<0.001
Spikevax + Spikevax + Comirnaty 0-13	100	.	.	0.026
Spikevax + Spikevax + Comirnaty 14-60	100	.	.	<0.001
Spikevax + Spikevax + Comirnaty 61+	100	.	.	0.041
Spikevax + Spikevax + Spikevax 0-13	100	.	.	<0.001
Spikevax + Spikevax + Spikevax 14-60	100	.	.	<0.001
Spikevax + Spikevax + Spikevax 61+	100	.	.	0.002
Vaxzevria 0-20	100	.	.	0.079
Vaxzevria 21-83	67	-163	96	.
Vaxzevria 84+	100	.	.	0.173
Vaxzevria + Vaxzevria 0-13	100	.	.	0.518
Vaxzevria + Vaxzevria 14-90	77	1	95	.
Vaxzevria + Vaxzevria 91-180	82	54	93	.
Vaxzevria + Vaxzevria 181+	50	-64	85	.
Vaxzevria + Vaxzevria + Comirnaty 0-13	100	.	.	0.002
Vaxzevria + Vaxzevria + Comirnaty 14-60	100	.	.	<0.001
Vaxzevria + Vaxzevria + Comirnaty 61+	48	-297	93	.
Vaxzevria + Vaxzevria + Spikevax 0-13	100	.	.	0.028
Vaxzevria + Vaxzevria + Spikevax 14-60	100	.	.	<0.001
Vaxzevria + Vaxzevria + Spikevax 61+	100	.	.	0.460

MLE, maximum likelihood estimate;

LCI/UCI, lower/upper limit of the 95% Wald confidence interval

¹ Likelihood-ratio test

Supplementary Table 8: VE against Covid-19-related hospital admission by age group Vaccine effectiveness (in %) quantified as 1 minus the hazard ratio stratified by age in years and adjusted for sex, region of residence, residence in a long-term care facility, influenza vaccination in 2019–2020, number of nights hospitalized between 2015 and 2019 and presence of predisposing comorbidities. Estimates marked by an asterisk are statistically significantly different from the corresponding estimates for 70–79-year-olds.

	70-79	80-89	90-115
Comirnaty 0-20	48	44	34
Comirnaty 21-83	71	46*	77
Comirnaty 84+	64	70	43
Comirnaty + Comirnaty 0-13	88	76	100
Comirnaty + Comirnaty 14-90	95	89*	93
Comirnaty + Comirnaty 91-180	88	83*	86
Comirnaty + Comirnaty 181+	79	65*	50*
Comirnaty + Comirnaty + Comirnaty 0-13	92	90	64*
Comirnaty + Comirnaty + Comirnaty 14-60	97	94*	93
Comirnaty + Comirnaty + Comirnaty 61+	91	93	82
Comirnaty + Comirnaty + Spikevax 0-13	94	67*	100
Comirnaty + Comirnaty + Spikevax 14-60	96	88	79
Comirnaty + Comirnaty + Spikevax 61+	50	73	18
Spikevax 0-20	60	100	-8
Spikevax 21-83	77	82	-91*
Spikevax 84+	100	34	100
Spikevax + Spikevax 0-13	100	61	100
Spikevax + Spikevax 14-90	100	90	100
Spikevax + Spikevax 91-180	90	76*	68
Spikevax + Spikevax 181+	83	76	82
Spikevax + Spikevax + Comirnaty 0-13	100	79	-55
Spikevax + Spikevax + Comirnaty 14-60	92	96	100
Spikevax + Spikevax + Comirnaty 61+	100	100	100
Spikevax + Spikevax + Spikevax 0-13	92	93	61
Spikevax + Spikevax + Spikevax 14-60	100	96	84
Spikevax + Spikevax + Spikevax 61+	96	93	80
Vaxzevria 0-20	28	100	100
Vaxzevria 21-83	69	100	100
Vaxzevria 84+	45	-237	100
Vaxzevria + Vaxzevria 0-13	100	100	100
Vaxzevria + Vaxzevria 14-90	87	20	100
Vaxzevria + Vaxzevria 91-180	76	100	100
Vaxzevria + Vaxzevria 181+	44	51	100
Vaxzevria + Vaxzevria + Comirnaty 0-13	86	100	100
Vaxzevria + Vaxzevria + Comirnaty 14-60	98	100	100
Vaxzevria + Vaxzevria + Comirnaty 61+	100	-188	100
Vaxzevria + Vaxzevria + Spikevax 0-13	92	100	100
Vaxzevria + Vaxzevria + Spikevax 14-60	100	100	100
Vaxzevria + Vaxzevria + Spikevax 61+	45	100	100

Supplementary Table 9: VE against Covid-19-related hospital admission by presence of comorbidities Vaccine effectiveness (in %) quantified as 1 minus the hazard ratio stratified by presence of predisposing comorbidities and adjusted for age, sex, region of residence, residence in a long-term care facility, influenza vaccination in 2019–2020 and number of nights hospitalized between 2015 and 2019. Estimates marked by an asterisk are statistically significantly different from the corresponding estimates for individuals without predisposing comorbidities.

	None	Moderate	High
Comirnaty 0-20	47	53	46
Comirnaty 21-83	69	80	53
Comirnaty 84+	62	70	65
Comirnaty + Comirnaty 0-13	100	90	72
Comirnaty + Comirnaty 14-90	93	95	92
Comirnaty + Comirnaty 91-180	92	83*	84*
Comirnaty + Comirnaty 181+	79	70	68
Comirnaty + Comirnaty + Comirnaty 0-13	94	90	88
Comirnaty + Comirnaty + Comirnaty 14-60	99	95*	94*
Comirnaty + Comirnaty + Comirnaty 61+	97	91*	89*
Comirnaty + Comirnaty + Spikevax 0-13	96	94	81
Comirnaty + Comirnaty + Spikevax 14-60	98	89	93
Comirnaty + Comirnaty + Spikevax 61+	100	73	35
Spikevax 0-20	71	100	60
Spikevax 21-83	87	72	57
Spikevax 84+	100	29	79
Spikevax + Spikevax 0-13	100	100	73
Spikevax + Spikevax 14-90	94	100	97
Spikevax + Spikevax 91-180	92	84	81
Spikevax + Spikevax 181+	100	75	74
Spikevax + Spikevax + Comirnaty 0-13	100	67	86
Spikevax + Spikevax + Comirnaty 14-60	100	85	94
Spikevax + Spikevax + Comirnaty 61+	100	100	100
Spikevax + Spikevax + Spikevax 0-13	100	73	92
Spikevax + Spikevax + Spikevax 14-60	100	98	96
Spikevax + Spikevax + Spikevax 61+	100	86	94
Vaxzevria 0-20	26	100	4
Vaxzevria 21-83	100	-11	78
Vaxzevria 84+	-158	-39	100
Vaxzevria + Vaxzevria 0-13	100	100	100
Vaxzevria + Vaxzevria 14-90	100	100	63
Vaxzevria + Vaxzevria 91-180	84	89	64
Vaxzevria + Vaxzevria 181+	77	59	4
Vaxzevria + Vaxzevria + Comirnaty 0-13	100	100	68
Vaxzevria + Vaxzevria + Comirnaty 14-60	100	86	100
Vaxzevria + Vaxzevria + Comirnaty 61+	100	100	82
Vaxzevria + Vaxzevria + Spikevax 0-13	76	100	100
Vaxzevria + Vaxzevria + Spikevax 14-60	100	100	100
Vaxzevria + Vaxzevria + Spikevax 61+	100	-192	100

Supplementary Table 10: VE against Covid-19-related hospital admission in 2021 Q4, i.e., between October 01 and December 31. Vaccine effectiveness (in %) quantified as 1 minus the hazard ratio adjusted for age, sex, region of residence, residence in a long-term care facility, influenza vaccination in 2019–2020, number of nights hospitalized between 2015 and 2019 and presence of predisposing comorbidities.

	Cases	P-years	MLE	LCI	UCI	p-value ¹
Not vaccinated	148	11060
Comirnaty 0-20	<5	413	64	-46	91	.
Comirnaty 21-83	<5	776	60	-9	85	.
Comirnaty 84+	14	3351	68	45	82	.
Comirnaty + Comirnaty 0-13	<5	759	82	27	96	.
Comirnaty + Comirnaty 14-90	6	4712	90	78	96	.
Comirnaty + Comirnaty 91-180	156	103843	89	85	91	.
Comirnaty + Comirnaty 181+	73	19446	78	71	84	.
Comirnaty + Comirnaty + Comirnaty 0-13	23	16540	92	88	95	.
Comirnaty + Comirnaty + Comirnaty 14-60	16	18320	96	93	98	.
Comirnaty + Comirnaty + Comirnaty 61+	<5	1309	93	71	98	.
Comirnaty + Comirnaty + Spikevax 0-13	0	809	100	.	.	<0.001
Comirnaty + Comirnaty + Spikevax 14-60	<5	354	73	-8	93	.
Comirnaty + Comirnaty + Spikevax 61+	0	100	100	.	.	0.028
Spikevax 0-20	0	73	100	.	.	0.142
Spikevax 21-83	<5	196	59	-192	94	.
Spikevax 84+	<5	633	91	37	99	.
Spikevax + Spikevax 0-13	0	131	100	.	.	0.038
Spikevax + Spikevax 14-90	<5	865	92	42	99	.
Spikevax + Spikevax 91-180	22	12412	88	81	93	.
Spikevax + Spikevax 181+	6	2086	87	70	94	.
Spikevax + Spikevax + Comirnaty 0-13	<5	481	78	12	95	.
Spikevax + Spikevax + Comirnaty 14-60	<5	458	82	27	96	.
Spikevax + Spikevax + Comirnaty 61+	0	15	100	.	.	0.307
Spikevax + Spikevax + Spikevax 0-13	<5	1287	93	73	98	.
Spikevax + Spikevax + Spikevax 14-60	0	1148	100	.	.	<0.001
Spikevax + Spikevax + Spikevax 61+	0	29	100	.	.	0.151
Vaxzevria 0-20	0	<5	100	.	.	0.951
Vaxzevria 21-83	0	<5	100	.	.	0.810
Vaxzevria 84+	<5	194	62	-173	95	.
Vaxzevria + Vaxzevria 0-13	0	<5	100	.	.	0.898
Vaxzevria + Vaxzevria 14-90	0	295	100	.	.	0.023
Vaxzevria + Vaxzevria 91-180	21	8055	79	66	87	.
Vaxzevria + Vaxzevria 181+	6	412	20	-84	65	.
Vaxzevria + Vaxzevria + Comirnaty 0-13	<5	528	89	23	99	.
Vaxzevria + Vaxzevria + Comirnaty 14-60	<5	283	83	-22	98	.
Vaxzevria + Vaxzevria + Comirnaty 61+	0	14	100	.	.	0.375
Vaxzevria + Vaxzevria + Spikevax 0-13	0	157	100	.	.	0.013
Vaxzevria + Vaxzevria + Spikevax 14-60	0	42	100	.	.	0.175
Vaxzevria + Vaxzevria + Spikevax 61+	0	<5	100	.	.	0.700

MLE, maximum likelihood estimate;

LCI/UCI, lower/upper limit of the 95% Wald confidence interval

¹ Likelihood-ratio test

Supplementary Table 11: VE against Covid-19-related hospital admission in 2022 Q1, i.e., between January 01 and February 19. Vaccine effectiveness (in %) quantified as 1 minus the hazard ratio adjusted for age, sex, region of residence, residence in a long-term care facility, influenza vaccination in 2019–2020, number of nights hospitalized between 2015 and 2019 and presence of predisposing comorbidities.

	Cases	P-years	MLE	LCI	UCI	p-value ¹
Not vaccinated	145	5121
Comirnaty 0-20	<5	100	67	-134	95	.
Comirnaty 21-83	6	330	36	-44	72	.
Comirnaty 84+	6	606	62	13	83	.
Comirnaty + Comirnaty 0-13	<5	164	79	-49	97	.
Comirnaty + Comirnaty 14-90	6	2148	91	79	96	.
Comirnaty + Comirnaty 91-180	12	1894	76	56	86	.
Comirnaty + Comirnaty 181+	75	6450	61	48	71	.
Comirnaty + Comirnaty + Comirnaty 0-13	15	4227	87	77	92	.
Comirnaty + Comirnaty + Comirnaty 14-60	63	45889	95	94	97	.
Comirnaty + Comirnaty + Comirnaty 61+	64	20872	90	87	93	.
Comirnaty + Comirnaty + Spikevax 0-13	9	1934	85	70	92	.
Comirnaty + Comirnaty + Spikevax 14-60	11	6190	94	89	97	.
Comirnaty + Comirnaty + Spikevax 61+	7	416	48	-13	76	.
Spikevax 0-20	<5	40	36	-355	91	.
Spikevax 21-83	<5	75	64	-156	95	.
Spikevax 84+	<5	122	14	-132	68	.
Spikevax + Spikevax 0-13	0	32	100	.	.	0.117
Spikevax + Spikevax 14-90	<5	341	92	43	99	.
Spikevax + Spikevax 91-180	<5	362	90	28	99	.
Spikevax + Spikevax 181+	8	860	72	43	86	.
Spikevax + Spikevax + Comirnaty 0-13	0	168	100	.	.	0.002
Spikevax + Spikevax + Comirnaty 14-60	<5	1466	96	82	99	.
Spikevax + Spikevax + Comirnaty 61+	0	529	100	.	.	<0.001
Spikevax + Spikevax + Spikevax 0-13	<5	697	86	56	96	.
Spikevax + Spikevax + Spikevax 14-60	5	4529	97	92	99	.
Spikevax + Spikevax + Spikevax 61+	<5	1350	92	79	97	.
Vaxzevria 21-83	0	<5	100	.	.	0.894
Vaxzevria 84+	<5	37	8	-558	87	.
Vaxzevria + Vaxzevria 14-90	0	<5	100	.	.	0.865
Vaxzevria + Vaxzevria 91-180	<5	140	41	-140	86	.
Vaxzevria + Vaxzevria 181+	10	652	43	-10	70	.
Vaxzevria + Vaxzevria + Comirnaty 0-13	<5	383	80	19	95	.
Vaxzevria + Vaxzevria + Comirnaty 14-60	<5	2252	98	89	100	.
Vaxzevria + Vaxzevria + Comirnaty 61+	<5	365	90	27	99	.
Vaxzevria + Vaxzevria + Spikevax 0-13	<5	313	89	21	98	.
Vaxzevria + Vaxzevria + Spikevax 14-60	0	1075	100	.	.	<0.001
Vaxzevria + Vaxzevria + Spikevax 61+	<5	60	40	-336	92	.

MLE, maximum likelihood estimate;

LCI/UCI, lower/upper limit of the 95% Wald confidence interval

¹ Likelihood-ratio test


Supplementary Table 12: Negative control outcome analysis Ratio comparing the hazard of injury, poisoning and certain other consequences of external causes in vaccinated study subjects with the corresponding hazard in the unvaccinated, adjusted for age, sex, region of residence, residence in a long-term care facility, influenza vaccination in 2019–2020, number of nights hospitalized between 2015 and 2019 and presence of predisposing comorbidities. Estimates marked by an asterisk are statistically significantly different from 1.

	Cases	P-years	MLE	LCI	UCI	p-value ¹
Not vaccinated	7795	240658
Comirnaty 0-20	1293	40567	0.92	0.87	0.98	.
Comirnaty 21-83	3698	113799	0.93	0.88	0.98	.
Comirnaty 84+	483	9565	1.09	0.98	1.20	.
Comirnaty + Comirnaty 0-13	924	26187	0.96	0.89	1.03	.
Comirnaty + Comirnaty 14-90	5092	141577	0.98	0.93	1.03	.
Comirnaty + Comirnaty 91-180	5025	153578	0.99	0.93	1.05	.
Comirnaty + Comirnaty 181+	1189	28151	1.13	1.04	1.23	.
Comirnaty + Comirnaty + Comirnaty 0-13	580	20288	1.00	0.90	1.11	.
Comirnaty + Comirnaty + Comirnaty 14-60	1798	62529	1.03	0.94	1.11	.
Comirnaty + Comirnaty + Comirnaty 61+	687	21550	1.01	0.90	1.12	.
Comirnaty + Comirnaty + Spikevax 0-13	74	2683	1.05	0.83	1.34	.
Comirnaty + Comirnaty + Spikevax 14-60	138	6353	0.87	0.72	1.05	.
Comirnaty + Comirnaty + Spikevax 61+	25	491	1.43	0.96	2.14	.
Spikevax 0-20	225	4858	1.18	1.03	1.35	.
Spikevax 21-83	617	13686	1.13	1.04	1.24	.
Spikevax 84+	116	1538	1.53	1.27	1.85	.
Spikevax + Spikevax 0-13	159	2992	1.28	1.09	1.50	.
Spikevax + Spikevax 14-90	850	16066	1.29	1.19	1.40	.
Spikevax + Spikevax 91-180	767	17008	1.23	1.13	1.34	.
Spikevax + Spikevax 181+	145	2848	1.31	1.10	1.56	.
Spikevax + Spikevax + Comirnaty 0-13	25	623	1.29	0.87	1.92	.
Spikevax + Spikevax + Comirnaty 14-60	69	1846	1.23	0.96	1.57	.
Spikevax + Spikevax + Comirnaty 61+	18	521	1.08	0.68	1.73	.
Spikevax + Spikevax + Spikevax 0-13	78	1913	1.29	1.02	1.62	.
Spikevax + Spikevax + Spikevax 14-60	224	5456	1.31	1.12	1.52	.
Spikevax + Spikevax + Spikevax 61+	62	1317	1.33	1.02	1.73	.
Vaxzevria 0-20	57	2727	0.82	0.63	1.07	.
Vaxzevria 21-83	224	7908	1.03	0.90	1.18	.
Vaxzevria 84+	21	452	1.62	1.06	2.50	.
Vaxzevria + Vaxzevria 0-13	35	1490	0.83	0.59	1.16	.
Vaxzevria + Vaxzevria 14-90	200	8150	0.90	0.78	1.04	.
Vaxzevria + Vaxzevria 91-180	213	8932	1.02	0.88	1.18	.
Vaxzevria + Vaxzevria 181+	22	1080	0.95	0.62	1.45	.
Vaxzevria + Vaxzevria + Comirnaty 0-13	22	893	1.19	0.78	1.81	.
Vaxzevria + Vaxzevria + Comirnaty 14-60	49	2487	0.98	0.73	1.31	.
Vaxzevria + Vaxzevria + Comirnaty 61+	6	372	0.82	0.37	1.85	.
Vaxzevria + Vaxzevria + Spikevax 0-13	10	460	0.99	0.53	1.85	.
Vaxzevria + Vaxzevria + Spikevax 14-60	27	1092	1.19	0.81	1.75	.
Vaxzevria + Vaxzevria + Spikevax 61+	<5	62	1.55	0.39	6.20	.

MLE, maximum likelihood estimate; LCI/UCI, lower/upper limit of the 95% Wald confidence interval


¹ Likelihood-ratio test

Supplementary Figure 1: Distribution of SARS-CoV-2 variants by calendar month A subset of SARS-CoV-2-positive specimens are regularly selected for sequencing to assess the distribution of SARS-CoV-2 variants in Finland. The results are recorded in the National Infectious Diseases Register. The figure shows the relative frequency of each variant between December 27, 2020, and February 19, 2022 in the subpopulation aged 70 years and over. The corresponding number of sequenced specimens as well as the percentage of specimens that were sequenced are given below the x-axis.



The Omicron subtype BA.2 accounted for 1% of all Omicron infections.

Supplementary Figure 2: Distribution of exposure states by calendar month Relative distribution of person-years in the study of vaccine effectiveness against Covid-19 hospitalization from December 27, 2020, to February 19, 2022.



Supplementary Figure 3: Number of cases by calendar month Number of Covid-19-related hospital admissions and Covid-19-related ICU admissions in the study, i.e., between December 27, 2020, and February 19, 2022.

